Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GRI Bio, Inc.VLON · Entity 8336 | Director | June 09, 2022 | June 10, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GRI Bio, Inc.
Report date June 09, 2022 · Filed June 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.51 · Expires 2032-06-09 | Direct | 7,500 |
Reported balance
After 2022-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-09 · Grant · Acquired 7,500 · Balance 7,500 F1: The stock option vests in four equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in four equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2022 Filed Jun 10, 2022 17:32 UTC | GRI Bio, Inc. VLON · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001824293-22-000056 · wf-form4_165488232409421.xml · derivative · entry 1 Ammer Richard · CIK 0001843671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2032-06-09 F1 · derivative.exercise_date: The stock option vests in four equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant. Read SEC document |
| May 14, 2021 Filed May 18, 2021 20:08 UTC | GRI Bio, Inc. VLON · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 10,204 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001104659-21-068838 · tm2116776-6_4.xml · derivative · entry 2 Ammer Richard · CIK 0001843671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,204 Underlying: Common Stock · 10,204 shares Expires 2031-05-14 F2 · derivative.exercise_date: The stock option vests as to 50% of the underlying shares of common stock on June 30, 2021, then in two equal installments on September 30, 2021 and December 31, 2021, such that the stock option fully vests on December 31, 2021. Read SEC document |
| May 14, 2021 Filed May 18, 2021 20:08 UTC | GRI Bio, Inc. VLON · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001104659-21-068838 · tm2116776-6_4.xml · derivative · entry 1 Ammer Richard · CIK 0001843671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-05-14 F1 · derivative.exercise_date: The stock option vests in 24 equal monthly installments such that the stock option is fully vested on the second annual anniversary of the date of grant. Read SEC document |
| February 12, 2021 Filed Feb 12, 2021 23:02 UTC | GRI Bio, Inc. VLON · Entity 8336 | OtherCommon Stock | 47,063 | $6.40 | $301,203.20 |
DisclosureSEC source: 0001104659-21-022190 · tm214979-8_4seq1.xml · nonDerivative · entry 1 Ammer Richard · CIK 0001843671 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By SALMON Pharma GmbH Disclosed balance after: 47,063 F1 · kind: Issued immediately prior to the closing of the initial public offering of the issuer's common stock in connection with the conversion of the promissory notes held by the reporting person, as disclosed in the prospectus, dated February 9, 2021, filed with the U.S. Securities and Exchange Commission on February 11, 2021, which forms a part of the Registration Statements on Form S-1 (File Nos. 333-249636 and 333-252925), originally filed on October 23, 2020, as amended. F2 · ownership.direct: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.